Applications of small-molecule activating agent and antagonist of serotonin receptor subtype 6 in preventing and treating alzheimer disease

Abstract

The invention belongs to the field of life science research, and in particular relates to applications of an antagonist of serotonin receptor subtype 6 in preparing amyloid protein beta-amyloid inhibitors. According to the applications, for the first time, the elisa experiment is adopted for proving that an activating agent and the antagonist targeting to the serotonin receptor subtype 6 can reduce the generation of the amyloid protein beta-amyloid on the human nerve cell line, in the cerebrospinal fluid of patients, the concentration change of beta-amyloid is earlier than the change of the tau protein level, the deposition of amyloid protein is also earlier than the occurrence of the clinical symptoms, and considering that the process from the accumulation of beta-amyloid small peptide tothe plaque formation depends on the concentration of beta-amyloid, the searching for the method for reducing the concentration of beta-amyloid is very important for treatment. Therefore, the disclosure for the fact that the activating agent and the antagonist targeting to the serotonin receptor subtype 6 can reduce the generation of beta-amyloid and for the related mechanism can provide the guiding significance of the clinical experiment for the treatment of the alzheimer disease and the further research and development of medicines.

Description

technical field [0001] The invention belongs to the field of life science research, and in particular relates to the use of an antagonist of serotonin receptor subtype 6 (HTR6) in the preparation of an amyloid (Aβ) inhibitor. Background technique [0002] Alzheimer's disease (AD), also known as senile dementia, is a degenerative disease of the central nervous system with insidious onset and slow progressive course, and is the most common type of senile dementia. According to the different origins in the population, AD can be divided into two types: sporadic and familial, of which about 5% are familial cases. Studies on such cases have shown that mutations in APP, PSEN1 and PSEN2 genes are associated with AD The pathogenesis of most other sporadic cases is not clear. According to the development of the disease, it can be divided into four stages. The first stage is often wrongly attributed to aging or stress, and it is generally some distance away from the exact pathological ...

AI Technical Summary

Problems solved by technology

[0007] 3) Anti-inflammatory treatment, the anti-AD effect of non-steroidal anti-inflammatory drugs may affect the process of AD by inhibiting the abnormal proliferation of microglial cells

[0009] 5) Drugs that interfere with β-amyloid deposition, etc. Since the etiological mechanis

Images